Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 291-299

  Pulsipher, Michael A ^a   Young, Neal S ^b   Tolar, Jakub ^c   Risitano, Antonio M ^d   Deeg, H Joachim ^e   Anderlini, Paolo ^f   Calado, Rodrigo ^b   Kojima, Seiji ^g   Eapen, Mary ^h   Harris, Richard ⁱ   Scheinberg, Phillip ^b   Savage, Sharon ^j   Maciejewski, Jaroslaw P ^k   Tiu, Ramon V ^k   DiFronzo, Nancy ^b   Horowitz, Mary M ^h   Antin, Joseph H ^l  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g Children's Medical Centre   (Japan)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k TAUSSIG CANCER INSTITUTE   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Blood and marrow transplantation; Immunosuppressive therapy; Severe aplastic anemia; Telomeres

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY;

AGE; ALLOIMMUNIZATION; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CLINICAL ASSESSMENT; CLINICAL DATA REPOSITORY; CLINICAL TRIAL (TOPIC); DATA COLLECTION METHOD; DIAGNOSTIC VALUE; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL COOPERATION; KIDNEY DYSFUNCTION; LONGITUDINAL STUDY; MEDICAL RESEARCH; NONHUMAN; NORTH AMERICA; ORGAN DONOR; OUTCOME ASSESSMENT; PATIENT CARE; POPULATION RESEARCH; QUALITY OF LIFE; REVIEW; SEVERE APLASTIC ANEMIA; TOXICITY; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY RADIATION;

AGING; ANEMIA, APLASTIC; BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSION; INTERNATIONALITY; NORTH AMERICA; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; REGISTRIES;

EID: 79551684829     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.028     Document Type: Review

References (49)

1. Issaragrisil S., Kaufman D.W., Anderson T., et al. The epidemiology of aplastic anemia in Thailand. Blood 2006, 107:1299-1307.
2. Young N.S., Calado R.T., Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006, 108:2509-2519.
3. Marsh J.C. Management of acquired aplastic anaemia. Blood Rev 2005, 19:143-151.
4. Schrezenmeier H., Passweg J.R., Marsh J.C., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007, 110:1397-1400.
5. Kahl C., Leisenring W., Deeg H.J., et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 2005, 130:747-751.
6. Schrezenmeier H., Marin P., Raghavachar A., et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993, 85:371-377.
7. Bacigalupo A., Bruno B., Saracco P., et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000, 95:1931-1934.
8. Socie G., Rosenfeld S., Frickhofen N., Gluckman E., Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000, 37:91-101.
9. Frickhofen N., Heimpel H., Kaltwasser J.P., Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003, 101:1236-1242.
10. Bacigalupo A., Locatelli F., Lanino E., Marsh J., Socie G., Passweg J. Fludarabine, cyclophosphamide with or without low dose TBI for alternative donor transplants in acquired aplastic anemia (SAA): a report from the EBMT-SAA Working Party. Biol Blood Marrow Transplant 2009, 15:5.
11. Bacigalupo A., Socie G., Lanino E., et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica 2010, 95:976-982.
12. Deeg H.J., O'Donnell M., Tolar J., et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006, 108:1485-1491.
13. Marsh J.C., Ball S.E., Cavenagh J., et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009, 147:43-70.
14. Kosaka Y., Yagasaki H., Sano K., et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008, 111:1054-1059.
15. Sloand E., Kim S., Maciejewski J.P., Tisdale J., Follmann D., Young N.S. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002, 100:1185-1191.
16. Gidvani V., Ramkissoon S., Sloand E.M., Young N.S. Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol 2007, 82:721-724.
17. Solomou E.E., Rezvani K., Mielke S., et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 2007, 110:1603-1606.
18. Chen J., Ellison F.M., Eckhaus M.A., et al. Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J Immunol 2007, 178:4159-4168.
19. Ball S.E., Gibson F.M., Rizzo S., Tooze J.A., Marsh J.C., Gordon-Smith E.C. Progressive telomere shortening in aplastic anemia. Blood 1998, 91:3582-3592.
20. Brummendorf T.H., Maciejewski J.P., Mak J., Young N.S., Lansdorp P.M. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001, 97:895-900.
21. Calado R.T., Young N.S. Telomere maintenance and human bone marrow failure. Blood 2008, 111:4446-4455.
22. Calado R.T. Telomeres and marrow failure. Hematology Am Soc Hematol Educ Program 2009, 338-343.
23. de la Fuente J., Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007, 11:584-594.
24. Dietz A.C., Orchard P.J., Baker K.S., et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2010 Apr 12, [E-pub ahead of print].
25. Nobili B., Rossi G., De Stefano P., et al. Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen. Br J Haematol 2002, 119:573-574.
26. Ju Z., Jiang H., Jaworski M., et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med 2007, 13:742-747.
27. Scheinberg P., Wu C.O., Nunez O., Young N.S. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009, 144:206-216.
28. Scheinberg P, Cooper J, Sloand E, Wu C, Calado R, Young N. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 304:1358-1364.
29. Rosenfeld S.J., Kimball J., Vining D., Young N.S. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995, 85:3058-3065.
30. Frickhofen N., Kaltwasser J.P., Schrezenmeier H., et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med 1991, 324:1297-1304.
31. Marsh J., Schrezenmeier H., Marin P., et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999, 93:2191-2195.
32. Scheinberg P., Nunez O., Young N.S. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006, 133:622-627.
33. Saracco P., Quarello P., Iori A.P., et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008, 140:197-205.
34. Scheinberg P., Nunez O., Wu C., Young N.S. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006, 133:606-611.
35. Scheinberg P., Wu C.O., Nunez O., Boss C., Sloand E.M., Young N.S. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009, 94:348-354.
36. Passweg J.R., Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?. Haematologica 2009, 94:310-312.
37. Risitano A.M., Selleri C., Serio B., et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010, 148:791-796.
38. Brodsky R.A., Chen A.R., Dorr D., et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010, 115:2136-2141.
39. Tisdale J.F., Maciejewski J.P., Nunez O., Rosenfeld S.J., Young N.S. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood 2002, 100:4668-4670.
40. Li Z., Yin S., Xie S., Ma L., Nie D., Xsu L. Treatment of severe aplastic anemia using high-dose cyclophosphamide alone in China. Haematologica 2000, 85:E06.
41. Maury S., Bacigalupo A., Anderlini P., et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009, 94:1312-1315.
42. Passweg J.R., Perez W.S., Eapen M., et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006, 37:641-649.
43. Deeg H.J., Socie G., Schoch G., et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996, 87:386-392.
44. Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993, 329:1152-1157.
45. Kollman C., Abella E., Baitty R.L., et al. Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors. Transplantation 2004, 78:89-95.
46. Yoshimi A., Kojima S., Taniguchi S., et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 2008, 14:1057-1063.
47. Chan K.W., McDonald L., Lim D., Grimley M.S., Grayson G., Wall D.A. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant 2008, 42:589-595.
48. Lacerda J.F., Martins C., Carmo J.A., et al. Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy-alone conditioning regimen in heavily transfused severe aplastic anemia. Biol Blood Marrow Transplant 2005, 11:399-400.
49. Tichelli A., Socie G., Henry-Amar M., et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med 1999, 130:193-201.